Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and ADME of Eliglustat in Healthy Men
NCT06143904Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of eliglustat in Gaucher disease type 1 (GD1) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 7 more. Started Jun 2009; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT06143904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143904.